The activity and sterility of reconstituted alteplase solution and the effectiveness of an alteplase dose-escalation protocol for the clearance of midlinecatheter and central-venous-access device ...

Patients were ineligible if endovascular treatment was planned at the time of randomization or if guideline-based contraindications for alteplase other than the time window were present.

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research suggests.

For patients with mainly mild posterior circulation ischemic stroke who do not receive thrombectomy, alteplase administered at 4.5 to 24 hours after onset results in higher frequency of functional ...

Researchers saw no significant difference between tenecteplase and alteplase in terms of effectiveness or safety outcomes, including functional independence at discharge. HealthDay News — For patients ...

Intravenous alteplase (recombinant tissue plasminogen activator) is restricted for use within 3 h from stroke onset by marketing authorizations. Some patients are treated beyond this approved time ...

Researchers found that the percentage of patients with functional independence at 90 days was higher in the alteplase group vs the standard treatment group. HealthDay News — For patients with ...

Alteplase administered 4.5 to 24 hours after mild posterior circulation ischemic stroke onset increases the likelihood of functional independence at 90 days compared to standard care.